Schering-Plough Corporation was a United States-based pharmaceutical company. It was founded in 1851 by Ernst Christian Friedrich Schering as Schering AG in Germany. In 1971, the Schering Corporation merged with Plough (founded by Memphis area entrepreneur Abe Plough in 1908 ) to form Schering-Plough. On November 4, 2009 Merck & Co. was merged with Schering-Plough with the new company taking the name of Merck & Co.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's April 15, 2008 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Schering-Plough Corp
Names of Lobbyists
Firm Hired Amount Schering-Plough Corp $4,230,000 Ruder Finn Inc $20,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Fed Budget & Appropriations,
- Labor, Antitrust & Workplace,
- Foreign Relations
Most Frequently Disclosed Bills
Bill No. Title H.R.2419 Farm Bill Extension Act of 2007 H.R.3161 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008 H.R.3162 Children's Health and Medicare Protection Act of 2007 S.21 Equity in Prescription Insurance and Contraceptive Coverage Act of 2007 S.1082 Medical Device User Fee Amendments of 2007 S.1859 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008 H.R.1038 H.R.2 Small Business and Work Opportunity Act of 2007 H.R.4 Medicare Prescription Drug Price Negotiation Act of 2007 H.R.976 Children's Health Insurance Program Reauthorization Act of 2007
RegulationsMentioned in 149 dockets; Submitted to 14 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Schering-Plough Corp" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Schering-Plough Corp
- Toggle 1 FDA Draft Guidance for Industry: Validation of Growth-Based Rapid Microbiological Methods for Sterility Testing of Cellular and Gene Therapy Products 2008
- Toggle 1 FDA Draft Guidance for Industry on Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products and Antimicrobial Susceptibility Testing Devices 2008
- Toggle 1 FDA Guidance for Industry on Questions and Answers Regarding the Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act 2007
- Toggle 1 FDA Opportunity for Hearing on a Proposal to Withdraw Approval of Prescription Polyethylene Glycol 3350 Abbreviated New Drug Applications. 2008
- Toggle 1 FDA Designating Additions to the Current List of Tropical Diseases in Section 1102 of the Food and Drug Administration Amendments Act; Public Hearing 2008
- Toggle 1 FDA Draft Guidance for Industry and Review Staff on Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route 2008
- Toggle 1 FDA Draft Guidance for Industry on Genotoxic and Carcinogenic Impurities in Drug Substances and Products 2008
- Toggle 1 FDA Draft Guidance for Industry on Control of Residual Solvents in Drug Products Marketed in the United States Availability 2008
- Toggle 1 FDA Acute Bacterial Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease; Draft Guidance for Industry 2008
- Toggle 1 FDA Draft Guidance for Industry Describing Product-Specific Bioequivalence Recommendations 2007
Mentions in Document Text
View all mentions data for Schering-Plough Corp
- Toggle 7 EPA Protection of Stratospheric Ozone: Allocation of Essential Use Allowances for Calendar Year 2008 2007
- Toggle 6 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designation (Epinephrine) 2007
- Toggle 5 EPA Protection of Stratospheric Ozone: Allocation of Essential Use Allowances for Calendar Year 2009 2008
- Toggle 4 FDA Docket Pertains to NADA/ANADA Notices 2008
- Toggle 3 FDA Over-the-Counter Cough and Cold Medications for Pediatric Use; Notice of Public Hearing 2008
- Toggle 3 EPA NESHAP: Group I Polymers and Resins (Epichlorohydrin Elastomers Production, HypalonTM Production, Nitrile Butadiene Rubber Production, Polybutadiene Rubber Production, and Styrene Butadiene Rubber and Latex Production); Marine Vessel Loading Operations; Mineral Wool Production; Pharmaceuticals Production; and Printing and Publishing Industry 2008
- Toggle 2 FDA Draft Guidance for Industry on Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products and Antimicrobial Susceptibility Testing Devices 2008
- Toggle 2 FDA Switch Allegra (Fexofendaine Hydrochloride), and Zyrtec (Cetirzine Hydrochloride) and Zyrtec D (Cetirizine Hydrochloride; Pseudophedrine Hydrochloride) from prescription drugs to over-the-counter - CLOSED 2007
- Toggle 2 FDA Standards for Standardized Numerical Identifier, Track and Trace, and Authentication for Prescription Drugs 2008
- Toggle 2 FDA Declare that Loratadine Orally-Dissolving Strips, 5mg and 10mg, for an abbreviated new drug application (ANDA) 2007
Contractor Misconduct1 Instances
This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.
More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.
|Misconduct Type||Hired By||Incident||Year||Disposition||Penalty|
|Securities||None||Clarinex Derivative Lawsuit||2008||Settlement||$9,800,000|
EPA Violations1 Enforcement Actions
Figures are based on data from the Environmental Protection Agency’s ECHO website. The ECHO database contains federal and state environmental enforcement actions. Data displayed here includes only those actions that began after 2000 and resulted in fines of over $1 million.
Actions where the company was the sole defendant are listed first. Actions where the company is one of multiple defendants are listed subsequently.
For more information see our EPA methodology page.
|Agere Systems, Et Al||Schering-Plough Corporation (+138 others)||2007||Elkton, Md||$11,300,000|
Advisory Committees2 people on 2 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Schering-Plough Corp" that sat on federal advisory committees.
- Toggle Department of Commerce 1 person on 1 committee
- Toggle Department of Health and Human Services 1 person on 1 committee